Novel Treatment of NF-1 Associated Malignant Peripheral Nerve Sheath Tumors

NF-1 相关恶性周围神经鞘瘤的新疗法

基本信息

批准号：
7537237
负责人：
STEVEN L. CARROLL
金额：
$ 30.09万
依托单位：
UNIVERSITY OF ALABAMA AT BIRMINGHAM
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
起止时间：
2007-12-07 至 2012-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7537237
关键词：
Animals Antibodies Benign Breast Adenocarcinoma Cell Line Cell Proliferation Cell Survival Clinical Trials Development Differentiation and Growth Dominant-Negative Mutation Drug Kinetics ERBB2 gene Effectiveness ErbB4 gene Family Foundations Future Gene Mutation Glial Growth Factor Growth Growth Factor HRAS gene Human Image In Vitro Individual Knowledge Light Luciferases Malignant Peripheral Nerve Sheath Tumor Mediating Mitogens Molecular Monoclonal Antibodies Mus Mutation NIH-III Mouse Neoplasms Neoplastic Schwann Cell Neuregulin 1 Neurofibromatoses Neurofibromatosis 1 Neurofibromatosis Type 1 Protein Pathogenesis Pathway interactions Patients Peripheral Nerve Sheath Neoplasm Peripheral Nervous System Neoplasms Pharmacodynamics Phosphotransferases Protein Isoforms Proteins RNA Interference Roche brand of trastuzumab Schwann Cells Signal Pathway Signaling Molecule Stimulation of Cell Proliferation Suppressor Mutations TP53 gene Testing Therapeutic Therapeutic Agents Toxic effect Transgenes Transgenic Mice Trastuzumab Tumor Cell Line Tumor Suppressor Genes Tumor Suppressor Proteins base effective therapy in vivo inhibitor/antagonist malignant breast neoplasm mouse model neoplastic cell neurofibroma neutralizing antibody novel overexpression preclinical study ras Proteins receptor research study response sciatic nerve small hairpin RNA therapeutic target tumor tumor growth tumorigenesis

项目摘要

DESCRIPTION (provided by applicant): Patients with neurofibromatosis type 1 (NF1) develop benign tumors of peripheral nerve known as neurofibromas and malignant peripheral nerve sheath tumors (MPNSTs), a highly aggressive form of Schwann cell neoplasm that arises from neurofibromas. Inappropriate stimulation by growth factors is thought to cooperate with mutations of tumor suppressor genes such as NF1 and p53 to promote MPNST tumorigenesis. We hypothesized that proteins from the neuregulin-1 (NRG-1) family of growth and differentiation factors are among the molecules promoting the proliferation and/or survival of neoplastic Schwann cells in MPNSTs. To test this hypothesis, we generated transgenic mice expressing the NRG-1 isoform glial growth factor-23 (GGF23) in Schwann cells (P0-GGF23 mice) and found that these animals develop multiple neurofibromas and MPNSTs. We have also found that human neurofibromas and MPNSTs coexpress multiple NRG-1 isoforms and their erbB receptors and that the proliferation of human MPNST cell lines is profoundly inhibited by treatment with the small molecular erbB inhibitors PD158780 and PD168393. Based on these preliminary studies, we hypothesize that constitutive activation of erbB receptors is essential for the proliferation and/or survival of human MPNST cells and that decreasing erbB activity with PD168393 and/or 4D5, the anti-erbB2 antibody from which Herceptin was derived, will retard the proliferation and survival of these cells. We will partner human MPNST cell lines, mouse lines derived from MPNSTs arising in P0-GGF23 mice and the P0- GGF23 mouse model to critically test the hypotheses that: 1) inhibition of the NRG-1 receptors (erbB2, erbB3 and/or erbB4) decreases the proliferation and/or survival of MPNST cells in vivo and 2) NRG-1 promotes the proliferation and/or survival of MPNST cells by activating specific neurofibromin-regulated Ras proteins and their downstream effectors. These studies will critically evaluate novel therapies for MPNSTs that utilize effective, existing erbB inhibitors and will establish a strong basis for the future development of even more effective therapies precisely targeting critical NRG-1 regulated cytoplasmic signaling molecules, alone or in combination with erbB inhibitors, in NF1-associated MPNSTs. Patients with neurofibromatosis type 1 (NF1) develop benign tumors of peripheral nerve known as neurofibromas, and malignant peripheral nerve sheath tumors (MPNSTs), a highly aggressive form of Schwann cell neoplasm that arises from neurofibromas. Inappropriate stimulation by growth factors is thought to cooperate with mutations of tumor suppressor genes such as NF1 and p53 to promote MPNST tumorigenesis.

描述（由申请人提供）：患有 1 型神经纤维瘤病 (NF1) 的患者会出现良性外周神经肿瘤，称为神经纤维瘤和恶性外周神经鞘瘤 (MPNST)，这是一种由神经纤维瘤引起的高度侵袭性雪旺细胞肿瘤。生长因子的不当刺激被认为与 NF1 和 p53 等肿瘤抑制基因的突变配合，促进 MPNST 肿瘤的发生。我们假设来自神经调节蛋白-1 (NRG-1) 生长和分化因子家族的蛋白质是促进 MPNST 中肿瘤性雪旺细胞增殖和/或存活的分子之一。为了检验这一假设，我们培育了在雪旺细胞中表达 NRG-1 同工型胶质生长因子 23 (GGF23) 的转基因小鼠（P0-GGF23 小鼠），并发现这些动物会出现多发性神经纤维瘤和 MPNST。我们还发现人类神经纤维瘤和 MPNST 共表达多种 NRG-1 亚型及其 erbB 受体，并且小分子 erbB 抑制剂 PD158780 和 PD168393 治疗可深度抑制人类 MPNST 细胞系的增殖。基于这些初步研究，我们假设 erbB 受体的组成型激活对于人类 MPNST 细胞的增殖和/或存活至关重要，并且用 PD168393 和/或 4D5（赫赛汀的抗 erbB2 抗体）降低 erbB 活性，会阻碍这些细胞的增殖和存活。我们将与人类 MPNST 细胞系、P0-GGF23 小鼠中产生的 MPNST 衍生的小鼠系以及 P0-GGF23 小鼠模型合作，严格测试以下假设：1) 抑制 NRG-1 受体（erbB2、erbB3 和/或 erbB4） ) 降低体内 MPNST 细胞的增殖和/或存活，并且 2) NRG-1 通过以下方式促进 MPNST 细胞的增殖和/或存活激活特定的神经纤维蛋白调节的 Ras 蛋白及其下游效应器。这些研究将严格评估利用有效的现有 erbB 抑制剂的 MPNST 新疗法，并将为未来开发更有效的疗法奠定坚实的基础，这些疗法精确靶向关键的 NRG-1 调节的细胞质信号分子，单独或与 erbB 抑制剂组合。与 NF1 相关的 MPNST。 1 型神经纤维瘤病 (NF1) 患者会出现周围神经良性肿瘤（称为神经纤维瘤）和恶性周围神经鞘瘤 (MPNST)，这是一种由神经纤维瘤引起的高度侵袭性雪旺细胞肿瘤。生长因子的不当刺激被认为与 NF1 和 p53 等肿瘤抑制基因的突变配合，促进 MPNST 肿瘤的发生。